@article{CJCR5708,
author = {Youwu Shi and Shengyu Zhou and Xiaohui He and Xiaohong Han and Shikai Wu and Feng Pan and Peng Liu and Yinyu Liu and Yingheng Lei and Hongzhi Zhang and Jianliang Yang and Yan Qin and Changgong Zhang and Sheng Yang and Liya Zhao and Kehuan Luo and Guanqing Wu and Yan Sun and Yuankai Shi},
title = {Autologous hematopoietic stem cell transplantation in chemotherapy-sensitive lymphoblastic lymphoma: treatment outcome and prognostic factor analysis},
journal = {Chinese Journal of Cancer Research},
volume = {27},
number = {1},
year = {2015},
keywords = {},
abstract = {Objective: The study evaluated the effectiveness of autologous hematopoietic stem cell transplantation (AHSCT) in the treatment of lymphoblastic lymphoma (LL).
Methods: We retrospectively analyzed the data from 41 patients with chemotherapy-sensitive LL who underwent hematopoietic stem cell transplantation (HSCT) from December 1989 to December 2009 in a single institution.
Results: HSCT was conducted as first-line consolidation therapy and salvage therapy in 36 and 5 patients, respectively. The median follow-up was 97.1 months (range, 24.6-173.1 months). The 5-year overall survival (OS) and event-free survival (EFS) rate were 64% and 47% for the initially treated patients, respectively, and were both 20% for the relapsed ones. Bone marrow (BM) involvement and chemotherapy cycles prior to transplantation were identified as significant prognostic factors for EFS in multivariate analysis.
Conclusions: These results confirm that AHSCT is a reasonable option for chemotherapy-sensitive LL patients in first complete remission (CR1).},
issn = {1993-0631}, url = {https://cjcr.amegroups.org/article/view/5708}
}